Fananserin

Fananserin
Clinical data
Other names	RP-62203; RP62203
Drug class	Serotonin 5-HT2A receptor antagonist; Dopamine D4 receptor antagonist
ATC code	None;
Identifiers
	IUPAC name 2-(3-(4-(p-Fluorophenyl)-1-piperazinyl)propyl)-2H-naphth(1,8-cd)isothiazole 1,1-dioxide;
CAS Number	127625-29-0 ;
PubChem CID	60785;
IUPHAR/BPS	5434;
ChemSpider	54781 ;
UNII	38QJ762ET6;
KEGG	D02656 ;
CompTox Dashboard (EPA)	DTXSID8046743 ;
Chemical and physical data
Formula	C23H24FN3O2S
Molar mass	425.52 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1CN(CCN1CCCN2C3=CC=CC4=C3C(=CC=C4)S2(=O)=O)C5=CC=C(C=C5)F;
	InChI InChI=1S/C23H24FN3O2S/c24-19-8-10-20(11-9-19)26-16-14-25(15-17-26)12-3-13-27-21-6-1-4-18-5-2-7-22(23(18)21)30(27,28)29/h1-2,4-11H,3,12-17H2 ; Key:VGIGHGMPMUCLIQ-UHFFFAOYSA-N ;
	(what is this?) (verify)

Fananserin (RP-62203) is a drug which acts as a potent antagonist at both the serotonin 5-HT_2A receptor,^[1] and the dopamine D₄ receptor,^[2] but without blocking other dopamine receptors such as the dopamine D₂ receptor.^[3] It has sedative^[4] and antipsychotic effects, and has been researched for the treatment of schizophrenia,^[5] although efficacy was less than expected and results were disappointing.^[6]